A new medicine that will be incorporated into the Unified Health System (SUS) can make life easier for people living with the human immunodeficiency virus (HIV). Called Dovato, the medicine combines two antiretrovirals already available in SUS and used in the treatment against the virus – Dolutegravir and Lamivudine. The difference is that now patients will be able to take a single pill a day.
“We are in the final bidding phase and distribution to the states should start by December. The co-formulation of the two drugs already incorporated represents an improvement of the existing protocols”, said the Ministry of Health.
According to the folder, the novelty should help in adherence to treatment, since it will be easier to do it on a daily basis, in addition to improving the quality of life of people living with HIV. The treatment requires people to take both Dolutegravir and Lamivudine daily.
living with HIV
HIV is the virus that causes Acquired Immunodeficiency Syndrome (AIDS), a disease that attacks the immune system, making the person’s body susceptible to a series of diseases and complications.
Although there is no cure for AIDS and no method to expel HIV from the body, treatment with antiretrovirals guarantees stability to the virus, preventing the onset of the disease or significantly delaying its progress, preventing secondary infections and complications.
With the treatment that is made available today by the SUS, with daily use of antiretrovirals, unlike the 1980s and 1990s, when the world saw an AIDS epidemic, many people with HIV do not manage to develop the disease, or, when they do, they live with it without major aggravations.
Source: CNN Brasil
I am an experienced journalist and writer with a career in the news industry. My focus is on covering Top News stories for World Stock Market, where I provide comprehensive analysis and commentary on markets around the world. I have expertise in writing both long-form articles and shorter pieces that deliver timely, relevant updates to readers.
